The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (10 mV). The carrier is in addition devoid of any surface sterically stabilizing agent. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.La présente invention concerne une composition pharmaceutique comprenant la combinaison de (i) au moins une nanoparticule biocompatible et de (ii) au moins un support comprenant au moins un composé pharmaceutique, à administrer à un sujet ayant besoin d'un tel composé pharmaceutique, laquelle combinaison de la ou des nanoparticules biocompatibles et du ou des supports comprenant le ou les composés pharmaceutiques potentialise l'efficacité du ou des composés d'intérêt. La dimension la plus longue de la nanoparticule biocompatible est généralement comprise entre environ 4 et environ 500 nm, et sa valeur absolue de charge de surface est d'au moins 10 mV (10 m V). Le support est en outre dépourvu de tout agent de stabilisation stérique de surface. L'invention concerne également une telle composition destinée à être utilisé
